Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

To describe the treatment patterns of Chinese NDMM patients receiving first-line immunotherapy in real-world settings.

To determine the clinical outcomes of Chinese NDMM patients receiving first-line immunotherapy in real-world settings.The real-world overall response rate (rwORR) of the entire population, as well as the rwORR of each treatment regimen.

To assess the depth of response in Chinese patients with NDMM receiving first-line immunotherapy in real-world settings, with the corresponding endpoint being minimal residual disease.

Disease stage classified according to the Revised International Staging System (R-ISS I, II, or III) at baseline.

Serum LDH concentration measured at baseline, reported in units per liter (U/L).

Patient age in years at the time of enrollment (baseline)

Biological sex recorded at baseline (male or female)

Type of monoclonal immunoglobulin (e.g., IgG, IgA, IgD, IgM, light chain only) determined at diagnosis.

Presence of gain or amplification of chromosome region 1q21 detected by FISH at baseline

Presence of ultra-high-risk genetic features defined as: TP53 biallelic inactivation, ≥2 high-risk cytogenetic lesions (e.g., del(17p), t(4;14), amp(1q)), circulating plasma cells ≥2%, or primary refractory disease